Top 100 PAA Option Holders as at 29/12/2020 with only one variation.variations., page-46

We know the MND trial aims to determine the tolerability, safety and efficacy of oral MPL. Its been announced that MPL was well tolerated by all the first cohort patients and we are almost certain it will satisfy all safety requirements trial key metrics especially given previous trial results.

I would therefore suggest that given all 6 patients have elected to continue with the trial as cohort 3 patients then the first dosing must have proven safe and must have also shown some positive results with regard to its effiicacy. I make this assumption on the basis that those with MND are in a sprint to the finish line and as such can not waste 1-day trialing a drug/molecule that had no beneficiial impact. I truly believe their decision to continue is like shouting from the rooftops that there have been very real signs of efficacy.

Desperately waiting for the cohort 1 full trial results which maybe be 1-2 weeks (max) away

I therefore think @NZ Trader can say goodbye to his 600,000 shares very soon and goodluck to him as long as he stays around to share his valuable market (PAA and baby bio industry) thoughts and evaluations